Emerging pharmacological approaches to the treatment of obesity

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 8, Issue 2, 2005, Pages 259-271

  Wasan, Kishor M ^a   Looije, Norbert A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Diet; Obesity; Pharmaceutical intervention; Physical activity; Thrifty genes

Indexed keywords

ADRENOMEDULLIN; ANTICONVULSIVE AGENT; ANTIESTROGEN; ANTIOBESITY AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; CLOZAPINE; DEXFENFLURAMINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FATTY ACID SYNTHASE; HISTAMINE H3 RECEPTOR ANTAGONIST; INSULIN; LEPTIN; MITOCHONDRIAL PROTEIN; NEUROLEPTIC AGENT; OLANZAPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHENTERMINE; PHYTOSTEROL; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; RIMONABANT; RISPERIDONE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; SUCROSE POLYESTER; TETRAHYDROLIPSTATIN; TOPIRAMATE; TRIACYLGLYCEROL LIPASE; UNINDEXED DRUG; ZIPRASIDONE;

ARTICLE; CLINICAL TRIAL; DIARRHEA; DIET THERAPY; DISEASE MODEL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EXERCISE; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GENETIC ANALYSIS; HEART DISEASE; HUMAN; INCIDENCE; LIFESTYLE; MUSCLE CRAMP; NONHUMAN; OBESITY; PATHOGENESIS; PHYSICAL ACTIVITY;

ADIPOSE TISSUE; ANIMALS; ANTI-OBESITY AGENTS; HUMANS; INSULIN; LEPTIN; OBESITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 27244438028     PISSN: 14821826     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Marx J. Cellular warriors at the battle of the bulge. Science 299:846-849 (2003).
2. Vega GL. Obesity, the metabolic syndrome, and cardiovascular disease. Am Heart J 142:1108-1116 (2001).
3. Jandacek RJ, Woods SC. Pharmaceutical approaches to the treatment of obesity. Drug Discov. Today 15:9;874-880, 2004.
4. Neel JV. Diabetes mellitus a "thrifty" genotype rendered detrimental by "progress"? Am J Hum Genet 14: 352-353, 1962.
5. Chakravarthy MV, Booth FW. Eating, exercise, and "thrifty" genotypes: connecting the dots toward an evolutionary understanding of modern chronic diseases. J Appl Physiol. 2004 Jan;96(1):3-10.
6. Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N. Engl. J. Med. 352(11): 1135-1137 (2005).
7. Ntambi JM, Miyazaki M. Recent insights into stearoyl-CoA desaturase-1. Curr. Opin. Lipidol. 14:255-261 (2003).
8. Minokoshi Y, Kahn BB. Role of AMP-activated protein kinase in leptin-induced fatty acid oxidation in muscle. Biochemical Society Transactions. 31(1): 196-201 (2003).
9. Niswender KD, Gallis B, Blevins JE, Corson MA, Schwartz MW, Baskin DG. Immunocytochemical detection of phosphatidylinositol 3-kinase activation by insulin and leptin. Journal of Histochemistry & Cytochemistry 51(3): 275-283 (2003).
10. Niswender KD, Schwartz MW. Insulin and leptin revisited: adiposity signals with overlapping physiological and intracellular signaling capabilities. Frontiers in Neuroendocrinology 24:1-10 (2003).
11. Liu Y, Nakagawa Y, Wang Y, Li R, Li X, Ohzeki T, Friedman TC. Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice. Diabetes. 52: 1409-1416 (2003).
12. Szanto I, Kahn CR. Selective interaction between leptin and insulin signaling pathways in a hepatic cell line. PNAS 97(5):2355-2360 (2000).
13. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, Kahn BB. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415: 339-343 (2002).
14. Hardie DG, Carling D, Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Ann Rev Biochem 67: 821-855 (1998).
15. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 277: E1-E10 (1999).
16. Stein SC, Woods A, Jones NA, Davison MD, Carling D. The regulation of AMP-activated protein kinase by phosphorylation. Biochem J. 345: 437-443 (2000).
17. Cohen P, Miyazaki M, Socci ND, Hagge-Greenberg A, Liedtke W, Soukas AA, Sharma R, Hudgins RC, Ntambi JM, Friedman JM. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 297:240-243 (2002).
18. Sun Y, Hao M, Luo Y, et al. Stearoyl-CoA desaturase inhibits ATP-binding cassette transporter A1-mediated cholesterol efflux and modulates membrane domain structure. J. Biol. Chem. 278: 5813-5820 (2003).
19. Cohen P, Zhao C, Cai X, et al. Selective deletion of leptin receptor in neurons leads to obesity. J Clin Invest 108: 1113-1121 (2001).
20. Miyazaki M, Ntambi JM. Physiological role of stearoyl-CoA desaturase. Prostaglandins Leukot Essent Fatty Acids 68: 113-121 (2003).
21. Bluher M, Michael MD, Peroni OD, Ueki K, Carter N, Kahn BB, Kahn CR. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev. Cell. 3:25-38 (2002).
22. Obici S, Feng Z, Karkanias G, Baskin DG, Rossetti L. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nature Neurosci 5(6): 566-572 (2002).
23. Zabolotny JM, Bence-Hanulee KK, Stricker-Krongrad A, et al. PTP1B regulates leptin signal transduction in vivo. Dev. Cell. 2(4): 385-387 (2002).
24. Wren AM, Small CJ, Fribbens CV, et al., The hypothalamic mechanisms of the hypophysiotropic action in ghrelin. Neuroendocrinology 76(5): 316-324 (2002).
25. Cummings DE, Weigle DS, Frayo RS, Breen PA, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N. Engl. J. Med. 346(21): 1623-1630 (2002).
26. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418(6898): 650-654 (2002).
27. M. Tschöp et al., Gut homone PYY(3-36) does not decrease food intake or body weight. Nature 418 (2004), pp. 650-654.
28. S.P. Vickers and C.T. Dourish, Serotonin receptor ligands and the treatment of obesity. Curr. Opin. Invest. Drugs 5 (2004), pp. 377-388.
29. H.M. Connolly et al., Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337 (1997), pp. 581-588.
30. S.L. McElroy et al., Are mood disorders and obesity related? A review for the mental health professional. J. Clin. Psychiatry 65 (2004), pp. 634-651.
31. J. Birt, Management of weight gain associated with antipsychotics. Ann. Clin. Psychiatry 15 (2003), pp. 49-58.
32. R.O. Brown et al., Topiramate and weight loss in patients with neurodevelopmental disabilities. Pharmacotherapy 22 (2002), pp. 831-835.
33. J. Epling, Is fluoxetine an effective therapy for weight loss in obese patients?. Am. Fam. Physician 68 (2003), pp. 2437-2438.
34. M.J. Nielsen et al., Food intake is inhibited by oral oleoylethanolamide. J. Lipid Res. 45 (2004), pp. 1027-1029.
35. S.C. Black, Cannabinoid receptor antagonists and obesity. Curr. Opin. Invest. Drugs 5 (2004), pp. 389-394.
36. T. Heinemann, G. Axtmann, K. von Bergmann. Comparison of intestinal absorption of cholesterol with different plant sterols in man. Eur. J. Clin. Invest. 23:827-831 (1993).
37. Wasan KM, Najafi S, Wong J, Kwong M, Pritchard PH: Assessing plasma lipid levels, body weight and hepatic and renal toxicity following chronic oral dministration of a water soluble phytostanol compound, FM-VP4, to gerbils. J Pharm Pharmaceut Sci 4:228-234, (2001).
38. Shimosawa T, Ogihara T, Matsui H, Asano T, Ando K, Fujita T. Deficiency of adrenomedullin induces insulin resistance by increasing oxidative stress. Hypertension 2003; 41:1080-1085.
39. Fukai N, Yoshimoto T, Sugiyama T, Ozawa N, Sato R, Shichiri N, Hirat Y. Concomitant expression of adrenomedullin and its receptor components in rat adipose tissues. Am J Physiol Endocrinol Metab 2005; 288: E56-E62.
40. B. Desvergne et al., Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol. Endocrinol. 18 (2004), pp. 1321-1332.
41. R.M. Evans et al., PPARs and the complex journey to obesity. Nat. Med. 10 (2004), pp. 355-361.
42. P. Ferre, The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53 suppl 1 (2004), pp. S43-S50.
43. P.J. Larsen et al., Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis. Diabetes 52 (2003), pp. 2249-2259.
44. M. Guzman et al., Oleoylethanolamide Stimulates Lipolysis by Activating the Nuclear Receptor Peroxisome Proliferator-activated Receptor {alpha} (PPAR-{alpha}). J. Biol. Chem. 279 (2004), pp. 27849-27854.
45. Hariharan, N. et al. (2001) Regulators of PPAR and their use in the treatment of obesity and insulin resistance. US patent 6,677,298.
46. R.J. Jandacek and M.R. Webb, Physical properties of pure sucrose octaesters. Chem. Phys. Lipids 22 (1978), pp. 163-176.
47. R.J. Jandacek et al., Olestra formulation and the gastrointestinal tract. Lipids 34 (1999), pp. 771-783.
48. G.A. Bray et al., A 9-mo randomized clinical trial comparing fat-substituted and fat-reduced diets in healthy obese men: the Ole Study. Am. J. Clin. Nutr. 76 (2002), pp. 928-934.
49. Ravussin E, Lillioja S, Knowler WC et al. Reduced rate of energy expenditure as a risk factor for body-weight gain. N Engl J Med 1988; 318: 467-472.
50. Bouchard C, Tremblay A, Despres JP et al. The response to long-term overfeeding in identical twins. N Engl J Med 1990; 322: 1477-1482.
51. Bouillaud F, Ricquier D, Mory G, Thibault J. Increased level of mRNA for the uncoupling protein in brown adipose tissue of rats during thermogenesis induced by cold exposure or norepinephrine infusion. J Biol Chem 1984; 259: 11583-11586.
52. Fleury C, Neverova M, Collins S et al. Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat Genet 1997; 15: 269-272.
53. Bao S, Kennedy A, Wojciechowski B, Wallace P, Ganaway E, Garvey WT. Expression of mRNAs encoding uncoupling proteins in human skeletal muscle: effects of obesity and diabetes. Diabetes 1998; 47: 1935-1940.
54. Millet L, Vidal H, Larrouy D, Andreelli F, Laville M, Langin D. mRNA expression of the long and short forms of uncoupling protein-3 in obese and lean humans. Diabetologia 1998; 41: 829-832.
55. Nordfors L, Hoffstedt J, Nyberg B et al. Reduced gene expression of UCP2 but not UCP3 in skeletal muscle of human obese subjects. Diabetologia 1998; 41: 935-939.
56. Oberkofler H, Liu YM, Esterbauer H, Hell E, Krempler F, Patsch W. Uncoupling protein-2 gene: reduced mRNA expression in intraperitoneal adipose tissue of obese humans. Diabetologia 1998; 41: 940-946.
57. Pinkney JH, Boss O, Bray GA, Bulmer K, Coppack SW, Mohamed-Ali V. Physiological relationships of uncoupling protein-2 gene expression in human adipose tissue in vivo. J Clin Endocrinol Metab 2000; 85: 2312-2317.
58. Millet L, Vidal H, Andreelli F et al. Increased uncoupling protein-2 and -3 mRNA expression during fasting in obese and lean humans. J Clin Invest 1997; 100: 2665-2670.
59. Arch JR. beta(3)-Adrenoceptor agonists: potential, pitfalls and progress. Eur J Pharmacol. 2002 Apr 12;440(2-3):99-107.
60. Conarello L, Li Z, Ronan J. Roy RS, et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 2003; 100: 6825-6830.
61. Hulin, B. et al. (2004) Cyclic amides as dipeptidyl peptidase IV inhibitors. US patent 6,710,040
62. Zhang ZY, Lee SY. PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity. Expert Opin Investig Drugs 2003; 12:223-233.
63. B.P. Kennedy, Role of protein tyrosine phosphatase-1B in diabetes and obesity. Biomed. Pharmacother. 53 (1999), pp. 466-470.
64. C.B. Lawrence et al., Alternative role for prolactin-releasing peptide in the regulation of food intake. Nat. Neurosci. 3 (2000), pp. 645-646.
65. W. Gu et al., The prolactin-releasing peptide receptor (GPR10) regulates body weight homeostasis in mice. J. Mol. Neurosci. 22 (2004), pp. 93-103.
66. Mhurchu CN, Poppitt SD, McGill AT, Leahy FE, Bennett DA, Lin RB, Ormrod D, Ward L, Strik C, Rodgers A. The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. Int J Obes Relat Metab Disord. 2004 Sep;28(9):1149-56.
67. 3 receptor antagonist. European J. Pharm. 2004: 487: 183-197.
68. Dobrzyn A, Ntambi JM. The role of stearoyl-CoA desaturase in body weight regulation. Trends Cardiovasc. Med. 2004: 14(2): 77-81.
69. US Department of Health and Human Services. Physical Activity and Health: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Prevention and Health Promotion, 1996.
70. Cordain L, Gotshall RW, Eaton SB, and Eaton SB III. Physical activity, energy expenditure and fitness: an evolutionary perspective. Int. J. Sports Med. 1998: 19: 328-335.